House AWP reform proposal
Rep. Charles Norwood (R-Ga.) introduces AWP reform bill based on "average sales price" April 3. Medicare would pay "120% of the average sales price," defined as "weighted average of all final sales prices to all purchasers." HHS would have discretion to use "cumulative averages sales price" to reimburse for all FDA "A" rated therapeutic equivalents. HR 1622 is similar to legislation sponsored by Rep. Pete Stark (D-Calif.), including proposed $100,000 fine for manufacturers failing to provide HHS with pricing information (1"The Pink Sheet" Jan. 27, p. 9)...
You may also be interested in...
The Centers for Medicare & Medicaid Services will address AWP reform administratively if Congress fails to act by May, CMS Administrator Tom Scully says
Increasing clinical trial complexity goes hand in hand with increased reliance on advanced-analysis software. Raj Indupuri of eClinical Solutions believes the company's product will lead this emerging market.
Merck KGaA’s short-course oral MS therapy Mavenclad may gain a boost from new data suggesting its use does not affect the beneficial response of patients to COVID-19 vaccines, as the research and manufacturing reagents and solutions business unit of the diversified big pharma reported a strong first quarter due to pandemic-related demand.